Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of tulisokibart versus placebo in rheumatoid arthritis
2025-521745-25-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Tulisokibart + methotrexate with Placebo + methotrexate (2 arms). Primary endpoint: Proportion of participants achieving ACR20 at Week 12. Planned start Nov 2025; status: authorised.
02
Drugs
tulisokibart
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2025-521745-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521745-25-00.